[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 5 sources · 5 days · First seen · Last updated

Israeli Alzheimer’s Immunotherapy Trials

Overview

An Israeli‑developed immune therapy, IBC‑Ab002, progressed through early clinical testing for Alzheimer’s disease. The first-in‑human Phase 1 trial, conducted by the Weizmann Institute, demonstrated a favorable safety profile and target engagement, supporting the concept that restoring age‑related immune function may modify neurodegeneration. Building on that result, a Phase 1b study across 11 sites in the United Kingdom, Israel and the Netherlands confirmed the drug’s tolerability in early‑stage patients, reporting no serious adverse events or amyloid‑related brain swelling. Biomarker analyses suggested reductions in neuronal injury and synaptic loss, hinting at possible disease‑modifying activity, though the sample size remained too small for definitive efficacy conclusions. The successive trials pave the way for larger efficacy studies in later phases.

Entities

Weizmann Institute of Science · Prof. Michal Schwartz · IBC‑Ab002 · Israel · anti‑PD‑L1 antibody

Timeline

  1. 22 days ago

    [HEALTH] 2 sources
    Anti-PD-L1 Antibody IBC‑Ab002 Shows Safety in Early Alzheimer’s Phase 1b Trial

    Phase 1b trial of IBC‑Ab002, an anti‑PD‑L1 antibody, was safe and lowered neuronal injury markers in early Alzheimer’s patients across the UK, Israel and the Netherlands.

  2. 26 days ago

    [HEALTH] 3 sources
    Israeli Immune Therapy Shows Safety in First Human Trial for Alzheimer’s

    Israeli‑developed antibody IBC‑Ab002 showed a safe profile in a Phase 1 trial, supporting a new immune‑based approach to Alzheimer’s treatment.

Sources

jwire.com.au · memesita.com · neurosciencenews.com · studyfinds.org · world-today-news.com